Open AccessDinutuximab (Unituxin)
Author(s) -
Reimbursement Team
Publication year - 2021
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2021.125
Subject(s) - reimbursement , medicine , irinotecan , temozolomide , drug , refractory (planetary science) , intensive care medicine , family medicine , pharmacology , cancer , chemotherapy , health care , political science , physics , colorectal cancer , law , astrobiology
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.This review assesses dinutuximab (Unituxin) 17.5 mg/m2 per day, administered as an IV infusion over 10 hours to 20 hours for 4 consecutive days per treatment cycle.Indication: For the treatment of high-risk neuroblastoma patients in their first relapse or determination of refractory disease in combination with irinotecan, temozolomide, andgranulocyte-macrophage colony-stimulating factor.